Malaria is a devastating disease that directly affects over half a million people each year with the most devastating and debilitating effects on young children. Antimalarial drug discovery by and large is focused on the identification of novel drugs to treat and prevent the disease due to the emergence and spread of Plasmodium strains resistant to existing medicines. In particular, artemisinin resistance has now spread from SE Asia and is firmly established in Africa (as reported at ASTMH in Seattle Oct 2022).
Merck, a large pharmaceutical company, paired up with an academic collaborator, Professor Alan Cowman, and his colleagues to do some malaria parasite drug hunting. The resulting collaboration identified robust targeted aspartyl protease screening hits that required some creative biochemical target identification to nail down the exact mechanism of the molecules. With some expert medicinal chemistry and detailed biological deciphering the team ended up with dual targeting molecules that are functionally active during the liver, blood, and mosquito stage of the parasite’s replication cycle.
Presented by David Olsen.
Undergraduate: Messiah College
Graduate school: Ph.D. U of Maryland, BioOrganic; enzymology
Postdoctoral: Max Planck Institute for Exp. Medicine Göttingen Germany: catalytic RNA
30+ yrs infectious diseases R&D experience at Merck & Co.
>110 peer reviewed publications
Areas of expertise:
ID drug hunting, proteases, nucleosides, HCV, HIV, Coronaviruses
Drug products: Zepatier (2 drugs), Vanihep, Efavirenz
Neglected diseases: TB, malaria, Ebola, monkey pox